68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.

Inclusion Criteria:Subject is aged 18 years or olderSigned Informed ConsentSubject is pathologically confirmed with a malignant tumorSubject is judged to be in good general condition by the investigator based on medical history, physical examination including vital signs and clinical laboratory tests, besides the diagnosis of malignant tumorFemale subjects should be post-menopausal or surgically sterile or using effective contraceptive with the negative pregnancy testExclusion Criteria:Subject has a previous or ongoing recurrent or chronic disease, other than malignant tumor, at high risk to interfere with the evaluation of the trial according to the judgment of the investigatorSubject with non-malignant lesions;Subject with the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.Subject is potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding